Moreover, ELISA using large-scale clinical cohort samples enables measurement of plasma apoA2-ATQ/AT levels to identify high-risk cases, including pancreatic cancer and IPMN (44, 45). This evidence concerns the gene APOA2 and familial pancreatic carcinoma.